Best Biopharma Outsourcing Companies in France
The 243 best Biopharma Outsourcing companies in France in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Provepharm Life Solutions.
France's Biopharma Outsourcing sector is busier than the headlines suggest, and this directory ranks the best biopharma outsourcing companies in France by disclosed equity funding and recent funding momentum across 243 tracked players. Total disclosed capital sits at $570M, with no unicorns yet, but the concentration at the top is real. CILcare leads at $42M raised, Oncodesign Services follows at $24M, and Genoskin has pulled in $9M. The global market behind all this activity is forecast to climb from roughly $28.7B in 2024 to $112.3B by 2032, a 5.8% CAGR driven by surging biologics demand and rising drug development costs. Bpifrance and Ardian are among the most active backers here, which tells you something about how seriously France's institutional money is treating this space.
So what's the structural story? Regulatory compliance pressure is tightening across the EU, and that's pushing more sponsors toward specialist outsourcing partners rather than building in-house. Hot themes right now include clinical trial outsourcing and clinical protocol design, and I'd watch both as deal activity picks up through the rest of this year. The median install growth of roughly 13% year-on-year across outsourcing and IT consulting apps signals that digital tooling inside these CROs is accelerating too. If you're sourcing a partner or benchmarking the competitive field, the funding tiers here give you a sharper starting point than most directories will.
- ResearchAndMarkets.com
Our analysis of 100 Biopharma Outsourcing companies
$10.3b in tracked funding; 68% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Biopharma Outsourcing companies in France
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Market signals (1y) | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Provepharm Life Solutions Pharmaceutical company dedicated towards the development and valorization of APIs and drug Products | $146M | 57 mo ago | 125 | 1998 | Michel Feraud CEO | — | 100 patents Synthesis of sulfonated triarylmethane dyes and crystalline indocyanine green for pharmaceutical imaging | — |
| 2 | M2i Life Sciences Provider of APIs, pheromones for crop protection and animal health | $79M | 81 mo ago | 200 | 2012 | Bruno Geny Co-Founder | — | — | 1 job opening · 4 launchs · 1 partnership |
| 3 | Isaltis Company developing and manufacturing high purity mineral salts for a wide range of industries | $55M | 135 mo ago | 160 | 2011 | — | — | — | — |
| 4 | CILcare Service to develop health products aiming to diagnose, prevent, delay the progression or treat hearing loss… | $42M | 18 mo ago | 28 | 2014 | — | — | — | 1 award |
| 5 | Kayentis Provider of electronic clinical outcome assessment solutions for clinical trials | $36M | 38 mo ago | 12 | 2003 | Philippe Berna Founder | — | — | 2 job openings · 2 launchs |
| 6 | Biose Provider of therapeutic macrobiotic ranges for human health | $34M | 71 mo ago | 2 | 2013 | — | — | 14 patents Mucoadhesive vaginal drug delivery systems for sustained antifungal candidiasis treatment | — |
| 7 | biose industrie Developer of drugs based on live microorganisms | $34M | 71 mo ago | 227 | 1951 | Stanislas Desjonqeères CEO | — | — | — |
| 8 | Oncodesign Services CRO focused on oncology drugs discovery, bioanalysis, and preclinical services | $24M | 28 mo ago | 210 | 1995 | — | — | 157 patents Patents concentrated in chemistry & materials | — |
| 9 | Neovacs CDMO focused on manufacturing of vaccines | $18M | 90 mo ago | — | 1993 | Hugo Brugiere CEO | — | 169 patents IL-4/IL-13 cytokine immunotherapies and mRNA vaccine formulations for immune modulation | — |
| 10 | GenOway Provider of transgenic rodent models and customized cell lines for preclinical development | $12M | 77 mo ago | 124 | 1999 | — | 6 signals ▼25% Earnings · Announcements | 15 patents Genetically engineered animal models with conditional KO/KI and advanced cloning vectors | 1 partnership |
| 11 | Genoskin In vitro human skin models for preclinical toxicity and efficacy testing | $9M | 9 mo ago | 39 | 2011 | Pascal Descargues CEO | — | 57 patents Ex vivo human skin platforms for inflammation, allergy, vaccine testing, and drug screening | 1 job opening · 2 expansions |
| 12 | Mapi Group Real world evidence studies and post-approval research services | $8M | 251 mo ago | 750 | 1990 | — | — | — | — |
| 13 | Biophta Developer of a pharmaceutical platform designed to transform ophthalmology by relieving patients from the… | $7M | 24 mo ago | 3 | 2020 | Jean Garrec founder & CEO | — | — | — |
| 14 | Generare Provider of drugs discovery services | $5M | 2 mo ago | — | 2022 | Vincent Libis Co-Founder | — | — | 1 job opening |
| 15 | Oncodesign Provider of preclinical assessment services for anticancer therapies 55Patents top 34%Product top 36%Moat top 40%Market top 42% All 10 signals ▾Patentstop 34% Producttop 36% Moattop 40% Markettop 42% Fundingtop 43% Innovationtop 44% Growthtop 45% Globaltop 49% Techbottom 47% Newsbottom 27% Patents: 157 patents matched (strict assignee match) · 20 filings since 2022 vs 77 in 2017-21 Product: 2 distinct product lines · Company stage: Acquired rank vs industry peers · Fliar Intelligence Index 55/100 | $5M | 3 mo ago | 238 | 1995 | — | — | 157 patents Macrocyclic small‑molecule kinase inhibitors for RIP2 and LRRK2 therapeutic targets | — |
| 16 | BCI Pharma Contract Research Organisation offering services mainly in cancer, neuropathic pain, inflammation and… | $5M | 99 mo ago | 13 | 2013 | — | — | — | — |
| 17 | Novasep CDMO offering its services for small molecules and biologics, and specializing in chromatography based… | $4M | 88 mo ago | 798 | 1995 | Pierre Lunel CEO | — | 53 patents Advanced multi‑column gradient liquid chromatography and isotope enrichment technologies. | — |
| 18 | L-up Provider of R&D funding program consulting and project management services | $4M | 65 mo ago | — | 2001 | Philippe Bellier Founder & Owner | — | — | 1 launch · 1 partnership |
| 19 | TransCure bioServices Developer of humanized animal models for preclinical studies | $4M | 47 mo ago | 81 | 2012 | Patrick Nef President & Chief Executive Officer | — | — | 1 internship |
| 20 | Orakl Oncology Orakl Oncology is a precision oncology start-up that enables the emergence of rare oncology by connecting… | $3M | 18 mo ago | — | 2023 | Fanny Jaulin Co-Founder & CEO | — | — | 1 job opening · 2 partnerships · 1 award |
| 21 | MitoProd Developer of technology for the production of ribonucleic acids | $3M | — | — | 2004 | Guillaume Plane Founder & CEO | — | — | — |
| 22 | OHRE Pharma Provider of marketing generic drugs and research development project services | $2M | 91 mo ago | 9 | 2014 | — | — | — | — |
| 23 | Cynbiose Preclinical CRO specializing in the development of non-human primate models for enabling PoC studies | $2M | 76 mo ago | 21 | 2008 | — | — | — | 1 job opening |
| 24 | Iconeus Digital animal brain imaging and analysis device for researchers | $2M | 44 mo ago | 30 | 2016 | — | — | 25 patents Medical ultrasound systems for real-time brain vascular and physiological monitoring | — |
| 25 | Medexprim Provider of clinical research services for biopharma sector | $2M | 69 mo ago | — | 2015 | — | — | — | — |
| 26 | CVasThera Manufacturer of drugs for multiple therapeutic areas | $2M | 63 mo ago | 4 | 2016 | Sylvie Grand Co-Founder | — | 14 patents PAR-1 antagonist drug formulations for treating inflammatory bowel disease | — |
| 27 | Ambiotis Provider of preclinical developmental services in inflammatory assays, mediators, and lipid analysis | $1M | 97 mo ago | 11 | 2007 | Marc Dubourdeau Founder & CEO | — | — | — |
| 28 | Flash BioSolutions CDMO specializing in lentiviral vector manufacturing for gene and cell therapies | $1M | 77 mo ago | — | 2005 | Jérôme Bédier CEO | — | — | — |
| 29 | Physiogenex Preclinical CRO focusing on metabolic disorders | $1M | 189 mo ago | 21 | 2002 | — | — | — | 1 job opening |
| 30 | Inoviem Scientific CRO specializing in researching drug-target interaction for discovering new therapeutics | $1M | 110 mo ago | 13 | 2011 | — | — | — | — |
| 31 | Atlantic Bone Screen Provider of preclinical services for bone and joint diseases | $1M | 159 mo ago | — | 2005 | Ronan Le Bot Founder & CEO | — | — | — |
| 32 | GenoSafe Provider of CRO and consulting company specializing in developing biological products | $1M | 101 mo ago | — | 2004 | Jean-Francois Col CEO | — | — | — |
| 33 | Diverchim CRO primarily offering synthetic and medicinal chemistry and chemoinformatics services for drug discovery and… | $1M | 131 mo ago | 46 | 2000 | — | — | 42 patents Cosmetic anti‑aging/depigmenting actives and cyclopropylboronic chiral intermediates | 1 job opening · 1 internship |
| 34 | Meddenovo Developer of computational biochemistry software for pharmaceutical research and development | $1M | 22 mo ago | — | 2021 | Ilke Marion Co-Founder | — | — | — |
| 35 | Smartox Biotechnology Discovery and the synthesis of peptides coming from animal venoms and related drug discovery services | $1M | 32 mo ago | 14 | 2009 | Michel De Waard Founder | — | — | — |
| 36 | Inel Manufacturer of real-time X-ray diffraction systems for laboratories | $1M | 124 mo ago | 19 | 2020 | — | — | 12 patents Multi‑modal material characterization systems and atmospheric cold‑plasma jet array technologies | — |
| 37 | Eurofins Provider of laboratory testing services, offering a broad range of analytical services to support the… | $1M | 73 mo ago | 169 | 1989 | Gilles Martin Founder & CEO | — | — | 1 job opening |
| 38 | Delpharm Pharmaceutical CDMO specialising in various finished dosage formulations | $969K | 60 mo ago | 6,000 | 1988 | — | 3 signals Leadership · Capital raise · Acquisition | 5 patents Injectable pharmaceutical formulations based on phloroglucinol production processes | 1 partnership · 1 expansion |
| 39 | Cenexi Pharmaceutical contract development and manufacturing providing pre-formulation and formulation services | $938K | 32 mo ago | 1,372 | 2004 | Philippe Mougin Founder & CEO | — | — | 8 job openings |
| 40 | Unither Contract development and manufacturing organization for proprietary and generic drugs | $904K | 43 mo ago | 2,000 | 1993 | — | 3 signals ▼62% Leadership | — | — |
| 41 | PMC Isochem Custom development manufacturing organization of API's & intermediates | $897K | 51 mo ago | 230 | 2017 | — | — | — | — |
| 42 | StaniPharm CDMO focused on manufacturing of drugs nano-particles | $811K | 74 mo ago | 11 | 2010 | Frantz Deschamps Co-Founder | — | 5 patents Formulating fine-particle pharmaceutical active ingredients for improved bioavailability. | — |
| 43 | Xentech Patient-Derived tumor Xenograft patform offering preclinical cancer models and services for translational… | $765K | 125 mo ago | 31 | 2006 | — | — | 10 patents Predictive cancer biomarker diagnostics for chemotherapy and PARP inhibitor response | — |
| 44 | Axplora Provider of contract based API products manufacturing services | $742K | 60 mo ago | 2,400 | 2018 | Sylke Hassel CEO | 10 signals Capital raise · Funding · Leadership | — | 1 partnership · 1 expansion |
| 45 | Rhenovia Pharma Provider of biosimulation technology for CNS drug discovery and development | $728K | 148 mo ago | — | 2007 | Serge Bischoff President & CEO | — | — | — |
| 46 | Synerlab Contract development and manufacturing organization | $604K | 65 mo ago | 1,300 | 2000 | — | — | — | — |
| 47 | Polymaris Developer of marine microorganism-derived biomolecules for industrial applications | $500K | 65 mo ago | 8 | 2008 | Anthony Courtois Co-Founder | — | — | — |
| 48 | PrediTox Provider of genotoxicity and carcinogenicity assessment services for various industries | $340K | 55 mo ago | — | 2017 | Laure Khoury Co-Founder & CEO | — | — | — |
| 49 | Fareva CDMO offering formulation development, manufacturing and packaging solutions | $317K | 60 mo ago | 13,000 | 1990 | — | — | 4 patents Nail polish removal devices and plastic aerosol dispensing systems for cosmetics | 1 partnership · 1 award |
| 50 | Medicen Paris Region Network supporting health innovation project development and funding | $311K | 45 mo ago | — | 2006 | Julien Ettersperger CEO | — | — | — |
Top 12 Biopharma Outsourcing companies in France
#1
Series A · Paris, Ile de France · founded 2022$5.5Mraised▾
Provider of drugs discovery services
- Apr 2026Series A$23.3M
- Oct 2024Seed$5.5M
#2
Acquired · Dijon, Bourgogne Franche Comte · founded 1995 · 238 employees$4.7Mraised▾
Oncodesign is an oncology preclinical CRO company that provides an assessment of anti-cancer therapies. It has three platforms, PREDICT - conventional in vitro and in vivo pharmacology, Chi-Mice - in vivo chimeric humanized models, and PharmImage - multimodal, non-invasive pharmaco-imaging. It uses Nanocyclix technology, for discovery activity that gives access to potent and selective macrocyclic kinase inhibitors.
- Mar 2026Grant (prize money)$6.9M
- May 2008Series A$4.7M
#3
Series A · Toulouse, Occitanie · founded 2011 · 39 employees$8.8Mraised▾
Genoskin, founded as a spin-off of from the French National Center for Scientific Research (CNRS) and The Paul Sabatier University in Toulouse is engaged in the development of ex vivo human skin models for preclinical efficacy and toxicity testing of potential drug candidates and might help in reducing the use of lab animals. The company claims to keep real human skin tissue alive for 7 days in human skin models and that they are the closest alternative to in vivo clinical testing. The company claims that its human skin collection process is as per the Declaration of Helsinki. The company has a BSL 2 cell culture rooms and 3D imaging technologies. They have proprietary human skin models such as Oncoskin, which can be used to study melanoma and Hyposkin to study subcutaneous injections.
- Sep 2025Series A$5.4M
- Sep 2025Conventional Debt$3.3M
- Aug 2019Grant (prize money)—
- Nov 2018Grant (prize money)$56.9K
#4
Series A · Montpellier, Occitanie · founded 2014 · 28 employees$42.3Mraised▾
CILcare is an R&D services company specialised in the development of drug candidates for hearing disorders (tinnitus, hearing loss) and otic disorders (ENT). The company provides preclinical services for research and development related to the hearing disorders area.
- Dec 2024Series A$42.3M
#5
Seed · Villejuif, Ile de France · founded 2023$3.1Mraised▾
Orakl Oncology is a precision oncology start-up that partners with Gustave Roussy, one of the world's top cancer centers, to connect patient tumors and enable the emergence of rare oncology. They have recently raised €3 million to develop their techbio platform for precision oncology.
- Dec 2024Seed$11.6M
- Oct 2023Seed$3.1M
#6
Late Stage · Dijon, Bourgogne Franche Comte · founded 1995 · 210 employees$24Mraised▾
CRO focused on oncology drugs discovery, bioanalysis, and preclinical services
- Jan 2024PE$24M
#7
Series D · Meylan, Auvergne Rhone Alpes · founded 2003 · 12 employees$36.2Mraised▾
Provider of electronic clinical outcome assessment solutions for clinical trials. The company delivers a platform adaptable to protocol, population, and questionnaire requirements. It offers tools for data management, real-time data access, and in-depth analytics. The platform provides multiple data collection modes and patient engagement features. It also facilitates integration with other clinical systems to streamline data flow.
- Mar 2023Series D$2.4M
- Mar 2023Conventional Debt$3M
- Dec 2020Series D$8.4M
- Oct 2016Series C$4M
#8
Late Stage · Marseille, Provence Alpes Cote d Azur · founded 1998 · 125 employees$145.9Mraised▾
Provepharm is a specialty pharma company, offering specialty products, preclinical services, API production & FDF for the clinical trial. The company products include methylene blue compound, methylthioninium chloride solution, methylene blue solution for injection, and methylrnr blue sterile solution.
- Sep 2021PE$142.3M
- May 2019Conventional Debt$47.6M
- Mar 2018PE—
- Dec 2011PE$3.6M
#9
Seed · Paris, Ile de France · founded 2020 · 3 employees$7.1Mraised▾
BIOPHTA is a pharmaceutical platform founded in 2020 that aims to improve the efficacy of eye treatments. The company has developed an ophthalmic insert to simplify eye treatment for patients with eye diseases.
- Jun 2024Seed$7.1M
#10
Seed · Villeurbanne, Auvergne Rhone Alpes · founded 2021$1.1Mraised▾
Developer of computational biochemistry software for pharmaceutical research and development. The company specializes in cyclic peptides, creating solutions for novel drug research and development studies. It combines experience in the field with original software. The technology platform assists drug hunters in designing novel drug candidates through a combination of artificial intelligence and physical computational approaches.
- Jul 2024Seed$1.1M
#11
Series B · Saint Cloud, Ile de France · founded 2012 · 200 employees$79.4Mraised▾
M2I Life Sciences offers APIs, pheromones for crop protection and animal health. The company is focusing on three businesses namely pharma, veterinary and agriculture. They provide custom synthesis and contract manufacturing services. The company synthesizes pheromonal molecules. They also offer chemicals such as ceramides, antioxidants, alkylglycerols, etc.
- Sep 2019Series B$66M
- Jun 2017Series A$13.4M
#12
Acquired · Clermont Ferrand, Auvergne Rhone Alpes · founded 2013 · 2 employees$34.2Mraised▾
Biose is a provider of therapeutic macrobiotic ranges for human health. The company offers pharmaceutical laboratories and biotechs around the world a complete and integrated offer to carry out the entire production process of these drugs, from process development to production of finished products.
- Jul 2020Series C$34.2M
- Jan 2019Grant (prize money)$314.9K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Biopharma Outsourcing coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in France
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 1,220 France-affiliated papers.
- Centre National de la Recherche Scientifique280
- Inserm169
- Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement144
- Ministry of Agriculture118
- AgroParisTech36
- Gene3→26
- Genome2→14
- Antibody1→10
- Cell culture1→10
- Mutant1→10
- Gene2→30
- Agriculture1→20
- Selection (genetic algorithm)2→18
- Resistance (ecology)2→16
- Population1→12
- Agriculture2→13
- Antibiotic resistance3→12
- Population1→9
- Public health1→8
- Context (archaeology)2→9
Where biotechnology is researched across France
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing biotechnology patents in France
France biotechnology patent filing is cooling — 34,222 filings from 8,000 assignees (2016–2025), led by Centre NAT RECH Scient, INST NAT Sante RECH MED, Sanofi; annual filings 3501→2745.
- Centre NAT RECH Scient10049
- INST NAT Sante RECH MED8302
- Sanofi3990
- Pasteur Institut3423
- Agronomique INST NAT RECH1334
- Cellectis1320
- PF Medicament1204
- Commissariat Energie Atomique1153
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.